Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells

References

• Altieri D. Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm. J Cell Biochem 2004; 92: 656–663
   PubMed Web of Science ®Google Scholar
• Bell GI, Merryweather JP, Sanchez-Pescador R, Stempien MM, Priestley L, Scott J. Sequence of a cDNA clone encoding human preproinsulin growth factor II. Nature 1984; 310: 775–777
   PubMed Web of Science ®Google Scholar
• Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann NY Acad Sci 2002; 957: 210–229
   PubMed Web of Science ®Google Scholar
• Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology 2000; 141(10)3657–3667
   PubMed Web of Science ®Google Scholar
• Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007; 26(54)7569–7575
   Google Scholar
• Daughaday WH, Trivedi B. Heterogeneity of serum peptides with immunoreactivity detected by a radioimmunoassay for proinsulin-like growth factor II E-domain. J Clin Endocrinol Metab 1992; 75: 641–645
   PubMed Web of Science ®Google Scholar
• De León DD, Wilson DM, Powers M, Rosenfeld RG. Effects of insulin-like growth factors and IGF receptor antibody on the proliferation of human breast cancer cells. Growth Factors 1992; 6(4)327–336
   PubMedGoogle Scholar
• DeLeon DD, Issa N, Nainani S, Asmerom Y. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisesnse IGF-II. Horm Metab Res 1999; 31: 142–147
   Google Scholar
• Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorogenesis. J Clin Invest 2004; 114(8)1117–1127
   PubMed Web of Science ®Google Scholar
• Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 2003; 523–524: 145–150
   PubMed Web of Science ®Google Scholar
• Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115: 575–585
   PubMed Web of Science ®Google Scholar
• Goel HL, Moro L, King M, Teider N, Centrella M, McCarthy TL, Holgado-Madruga M, Wong AJ, Marra E, Languino LR. Beta 1 integrins modulate cell adhesion by regulating IGF-II levels in the microenvironment. Cancer Res 2000; 66(1)331–342
   Google Scholar
• Gowan LK, Hampton B, Hill DJ, Schlueter RJ, Perdue JF. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology 1987; 121: 2050–2055
   Google Scholar
• Jang M, Cai L, Udeani GO, Showing KV, Thomas CF, Beecher CW, Fong HH. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275(5297)218–220
   PubMed Web of Science ®Google Scholar
• Kang-Park S, Lee YI, Lee YI. PTEN modulates IGF-II mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 2003; 545(2–3)203–208
   Google Scholar
• Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88: 1077–1083
   PubMed Web of Science ®Google Scholar
• Kim EJ, Holthuizen PE, Kim J, Park JH. Overexpression of mIGF-II leads to growth arrest in Caco-2 human colon cancer cells. Growth Horm IGF Res 2005; 15(1)64–71
   PubMedGoogle Scholar
• Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, Mann W, Petersen I, Heinzel T, Stauber RH. Nuclear export is essential for the tumor promoting activity of survivin. FASEB J 2007; 21: 207–216
   PubMedGoogle Scholar
• Lee Y, Han YH, Lee SY, Lee YI, Park SK, Moon HB. Activation of IGF-II signaling by mutant type p53: Physiological implications for potentiation of IGF-II signaling by p53 mutant. Mol Cell Endocrinol 2003; 203: 51–63
   PubMed Web of Science ®Google Scholar
• Li F, Yang J, Rammath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: What is the significance?. Int J Cancer 2005; 114: 509–512
   PubMed Web of Science ®Google Scholar
• Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334–1342
   PubMed Web of Science ®Google Scholar
• Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S. Human survivin is negatively regulated by wild type p53 and participates in p53 dependent apoptotic pathway. Oncogene 2000; 21: 2613–2622
   Google Scholar
• Perdue JF, LeBon TR, Kato J, Hampton B, Fujita-Yamaguchi Y. Binding specificities and transducing function of the different molecular weight forms of IGF-II on IGF-IR. Endocrinology 1991; 129(6)3101–3108
   Google Scholar
• Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244(2)164–171
   Google Scholar
• Schwartz GN, Szabo JM, Hudgins WR, Perdue JF. Two forms of insulin-like growth factor II enhanced granulopoiesis in serum-free liquid cultures of peripheral blood. Exp Hematol 1990; 18: 610
   Google Scholar
• Schwartz GN, Hudgins WR, Perdue JF. Glycosylated insulin-like growth factor II promoted expansion of granulocyte-macrophage colony-forming cells in serum-deprived liquid cultures of human peripheral blood cells. Exp Hematol 1993; 21(11)1447–1454
   Google Scholar
• Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127–134
   PubMed Web of Science ®Google Scholar
• Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007; 26: 2678–2684
   PubMed Web of Science ®Google Scholar
• Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7(7)602–608
   Google Scholar
• Vischioni B, Van Der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small cell luna cancer. Ann Oncol 2004; 15(11)1654–1660
   Google Scholar
• Vyas S, Asmerom Y, DeLeon DD. Resveratrol regulates IGF-II in breast cancer cells. Endocrinology 2005; 146(10)4224–4233
   PubMed Web of Science ®Google Scholar
• Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ, Sens DA, Garvin AJ, LeRoith D, Roberts CT. Increased expression of IGF-IR gene in Wilms tumor is correlated with modulation of IGF-IR activity by the WT1 tumor gene product. Proc Natl Acad Sci USA 1993; 90(12)5828–5832
   Google Scholar
• Yang CQ, Zhan X, Hu X, Kondepudi A, Perdue JF. The expression and characterization of human recombinant proIGF-II and a mutant that is defective in the O-glycosylation of its E-domain. Endocrinology 1996; 137(7)2766–2773
   PubMedGoogle Scholar
• Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5: 107–115
   PubMed Web of Science ®Google Scholar
• Zhang L, Kashanchi F, Zhan Q, Brady JN, Fornace AJ, Seth P, Helman LJ. Regulation of IGF-II P3 promoter by p53: A potential mechanism for tumorigenesis. Cancer Res 1996; 56: 1367–1373
   PubMedGoogle Scholar